Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs2252586
rs2252586
0.010 GeneticVariation BEFREE Similarly, stratified analysis of rs2252586 by stages revealed the similar trend, with OR of 1.26 (95 %CI = 1.17-1.35) in high-grade glioma and OR of 1.15 (95 %CI = 1.08-1.22) in low-grade glioma. 26243184

2016

dbSNP: rs2239647
rs2239647
0.010 GeneticVariation BEFREE We found that rs2239647 polymorphism was strongly associated with an increased risk of glioma (OR = 1.90, p = 0.007) and a worse prognosis for glioma, especially in high-grade glioma (HR = 1.67, p = 0.034). 31759389

2019

dbSNP: rs117677079
rs117677079
0.010 GeneticVariation BEFREE We found that rs117677079 polymorphism was strongly associated with an increased risk of glioma (OR 1.64, p = 0.003) and a worse prognosis for glioma, especially in high-grade glioma (HR 1.76, p = 0.005). 30536196

2019

dbSNP: rs17174393
rs17174393
A 0.700 CausalMutation CLINVAR

dbSNP: rs113488022
rs113488022
0.030 GeneticVariation BEFREE In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique clinicopathological features and may be a novel subset of high grade glioma. 30972500

2019

dbSNP: rs113488022
rs113488022
0.030 GeneticVariation BEFREE Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. 27799506

2016

dbSNP: rs113488022
rs113488022
0.030 GeneticVariation BEFREE Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. 29039591

2017

dbSNP: rs121913377
rs121913377
0.030 GeneticVariation BEFREE Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. 29039591

2017

dbSNP: rs121913377
rs121913377
0.030 GeneticVariation BEFREE Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. 27799506

2016

dbSNP: rs121913377
rs121913377
0.030 GeneticVariation BEFREE In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique clinicopathological features and may be a novel subset of high grade glioma. 30972500

2019

dbSNP: rs1424913115
rs1424913115
0.010 GeneticVariation BEFREE Logistic regression analysis showed that Leu</span>84Phe of MGMT gene and pathological grade were independent risk factors for the increase of TMZ resistance in patients with malignant gliomas. 28409559

2017

dbSNP: rs2298881
rs2298881
0.010 GeneticVariation BEFREE In a stratification analysis, we found that ERCC1 rs22</span>98881 variants showed an increased association with the risk of glioma in males, ever smokers, and high-grade glioma cases. 24782032

2014

dbSNP: rs1057519902
rs1057519902
0.010 GeneticVariation BEFREE Extraneural Metastases From a High-Grade Glioma (HGG) With an H3F3A G34R Mutation. 31139567

2019

dbSNP: rs1057519903
rs1057519903
0.010 GeneticVariation BEFREE A case report of adult cerebellar high-grade glioma with H3.1 K27M mutation: a rare example of an H3 K27M mutant cerebellar tumor. 29264735

2018

dbSNP: rs1553260624
rs1553260624
0.010 GeneticVariation BEFREE Extraneural Metastases From a High-Grade Glioma (HGG) With an H3F3A G34R Mutation. 31139567

2019

dbSNP: rs1057519904
rs1057519904
0.010 GeneticVariation BEFREE A case report of adult cerebellar high-grade glioma with H3.1 K27M mutation: a rare example of an H3 K27M mutant cerebellar tumor. 29264735

2018

dbSNP: rs121913500
rs121913500
0.050 GeneticVariation BEFREE In malignant glioma the presence of the IDH1 mutation (IDH1(R132H)) is associated with better clinical outcome. 26328938

2015

dbSNP: rs121913500
rs121913500
0.050 GeneticVariation BEFREE En bloc resection revealed a high-grade glioma with sarcomatous components that was immunoreactive for the R132H variant of IDH1 by antibody. 27153165

2017

dbSNP: rs121913500
rs121913500
0.050 GeneticVariation BEFREE We highlight the importance of Sox11 expression as a favourable prognosticator in glioblastomas. c-Met/nestin/IDH1-R132H expression phenotypes recapitulate the molecular subgroups of malignant glioma. 23619925

2013

dbSNP: rs121913500
rs121913500
0.050 GeneticVariation BEFREE Isocitrate dehydrogenase 1 gene (IDH1) R132H mutation status was also recently identified as a prognostic factor for malignant gliomas. 24929863

2014

dbSNP: rs121913500
rs121913500
0.050 GeneticVariation BEFREE Of 158 tumors with sufficient tissue, 110 (70 %) showed nuclear cMYC immunopositivity--most frequent (95 %, χ(2) p = 0.0248) and intense (mean 1.33, ANOVA p = 0.0179) in anaplastic astrocytomas versus glioblastomas (63 %) or low grade gliomas (74 %). cMYC expression associated with younger age as well as p53 immunopositivity (OR = 3.6, p = 0.0332) and mutant IDH1 (R132H) (OR = 7.4, p = 0.06) among malignant gliomas in our cohort. 23934175

2013

dbSNP: rs11554137
rs11554137
0.010 GeneticVariation BEFREE The SNP rs11554137 is independent of the occurrence of somatic mutation on IDH1 codon 132, but, per se, has a prognostic impact in malignant gliomas. 23184331

2013

dbSNP: rs1805015
rs1805015
0.010 GeneticVariation BEFREE The IL4R rs1805016 and rs1805015 TT genotypes were both found to be significantly associated with survival beyond 1 year among patients with high-grade glioma (HR, 0.44; 95% CI, 0.27-0.73 and HR, 0.63; 95% CI, 0.44-0.91, respectively). 18927306

2008

dbSNP: rs1805016
rs1805016
0.010 GeneticVariation BEFREE The IL4R rs1805016 and rs1805015 TT genotypes were both found to be significantly associated with survival beyond 1 year among patients with high-grade glioma (HR, 0.44; 95% CI, 0.27-0.73 and HR, 0.63; 95% CI, 0.44-0.91, respectively). 18927306

2008

dbSNP: rs1920116
rs1920116
0.020 GeneticVariation BEFREE Here we identify a new SNP associated with glioma risk, rs1920116 (near TERC), that reached genome-wide significance (Pcombined = 8.3 × 10(-9)) in a meta-analysis of genome-wide association studies (GWAS) of high-grade glioma and replication data (1,644 cases and 7,736 controls). 24908248

2014